Diosgenin, 4-hydroxyisoleucine, and fiber from fenugreek: Mechanisms of actions and potential effects on metabolic syndrome

Advances in Nutrition

Volumn 6, Issue 2, 2015, Pages 189-197

  Fuller, Scott ^a   Stephens, Jacqueline M ^a,b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

4 hydroxyisoleucine; Botanicals; Diosgenin; Fat cells; Fenugreek; Insulin action

Indexed keywords

4-HYDROXYISOLEUCINE; BIOLOGICAL MARKER; DIOSGENIN; FENUGREEK SEED MEAL; ISOLEUCINE; PLANT EXTRACT;

ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; DIETARY FIBER; HUMAN; INFLAMMATION; METABOLIC SYNDROME X; PATHOLOGY; PHARMACOLOGY; PHYTOTHERAPY; THERAPEUTIC USE; TRIGONELLA;

BIOMARKERS; DIETARY FIBER; DIOSGENIN; HUMANS; INFLAMMATION; ISOLEUCINE; METABOLIC SYNDROME X; PHYTOTHERAPY; PLANT EXTRACTS; TRIGONELLA;

EID: 84943238922     PISSN: 21618313     EISSN: 21565376     Source Type: Journal    
DOI: 10.3945/an.114.007807     Document Type: Review

References (93)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
2. Guariguata L, Whiting D, Weil C, Unwin N. The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. Diabetes Res Clin Pract 2011;94:322-32.
3. CDC. National diabetes fact sheet: National estimates and general information on diabetes and pre-diabetes in the United States. Atlanta (GA): US Department of Health and Human Services, CDC; 2011.
4. Saxena A, Vikram NK. Role of selected Indian plants in management of type 2 diabetes: a review. J Altern Complement Med 2004;10:369-78.
5. Wang E, Wylie-Rosett J. Review of selected Chinese herbal medicines in the treatment of type 2 diabetes. Diabetes Educ 2008;34:645-54.
6. Rizvi SI, Mishra N. Traditional Indian medicines used for the management of diabetes mellitus. J Diabetes Res 2013;3013:712092.
7. Wang Z, Wang J, Chan P. Treating type 2 diabetes mellitus with traditional Chinese and Indian medicinal herbs. Evid Based Complement Alternat Med 2013;2013:343594.
8. Yadav UC, Baquer NZ. Pharmacological effects of Trigonella foenumgraecum L. in health and disease. Pharm Biol 2014;52:243-54.
9. Balabanova Y, Klar S, Delere Y, Wilking H, Faber MS, Lassen SG, Gilsdorf A, Dupke S, Nitschke M, Sayk F, et al. Serological evidence of asymptomatic infections during Escherichia coli O104:H4 outbreak in Germany in 2011. PLoS ONE 2013;8:e73052.
10. Buchholz U, Bernard H, Werber D, Bohmer MM, Remschmidt C, Wilking H, Delere Y, van der Heiden M, Adlhoch C, Dreesman J, et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med 2011;365:1763-70.
11. Cohen PA. American roulette-contaminated dietary supplements. N Engl J Med 2009;361:1523-5.
12. Cohen PA. Hazards of hindsight-monitoring the safety of nutritional supplements. N Engl J Med 2014;370:1277-80.
13. Das S, Dey KK, Dey G, Pal I, Majumder A. MaitiChoudhury S, Kundu SC, Mandal M. Antineoplastic and apoptotic potential of traditional medicines thymoquinone and diosgenin in squamous cell carcinoma. PLoS ONE 2012;7:e46641.
14. Hirai S, Uemura T, Mizoguchi N, Lee JY, Taketani K, Nakano Y, Hoshino S, Tsuge N, Narukami T, Yu R, et al. Diosgenin attenuates inflammatory changes in the interaction between adipocytes and macrophages. Mol Nutr Food Res 2010;54:797-804.
15. Kalailingam P, Kannaian B, Tamilmani E, Kaliaperumal R. Efficacy of natural diosgenin on cardiovascular risk, insulin secretion, and beta cells in streptozotocin (STZ)-induced diabetic rats. Phytomedicine 2014;21:1154-61.
16. Pari L, Monisha P, Jalaludeen AM. Beneficial role of diosgenin on oxidative stress in aorta of streptozotocin induced diabetic rats. Eur J Pharmacol 2012;691:143-50.
17. Yamada T, Hoshino M, Hayakawa T, Ohhara H, Yamada H, Nakazawa T, Inagaki T, Iida M, Ogasawara T, Uchida A, et al. Dietary diosgenin attenuates subacute intestinal inflammation associated with indomethacin in rats. Am J Physiol 1997;273:G355-64.
18. Son IS, Kim JH, Sohn HY, Son KH, Kim JS, Kwon CS. Antioxidative and hypolipidemic effects of diosgenin, a steroidal saponin of yam (Dioscorea spp.), on high-cholesterol fed rats. Biosci Biotechnol Biochem 2007;71:3063-71.
19. Lima CM, Lima AK, Melo MG, Serafini MR, Oliveira DL, de Almeida EB, Barreto RS, Nogueira PC, Moraes VR, Oliveira ER, et al. Bioassayguided evaluation of Dioscorea villosa-an acute and subchronic toxicity, antinociceptive and anti-inflammatory approach. BMC Complement Altern Med 2013;13:195.
20. Qin Y, Wu X, Huang W, Gong G, Li D, He Y, Zhao Y. Acute toxicity and sub-chronic toxicity of steroidal saponins from Dioscorea zingiberensis C.H. Wright in rodents. J Ethnopharmacol 2009;126:543-50.
21. Tharaheswari M, Jayachandra Reddy N, Kumar R, Varshney KC, Kannan M, Sudha Rani S. Trigonelline and diosgenin attenuate ER stress, oxidative stress-mediated damage in pancreas and enhance adipose tissue PPARgamma activity in type 2 diabetic rats. Mol Cell Biochem 2014;396:161-74.
22. Saravanan G, Ponmurugan P, Deepa MA, Senthilkumar B. Modulatory effects of diosgenin on attenuating the key enzymes activities of carbohydrate metabolism and glycogen content in streptozotocin-induced diabetic rats. Can J Diabetes 2014;38:409-14.
23. Sangeetha MK. ShriShri Mal N, Atmaja K, Sali VK, Vasanthi HR. PPAR's and diosgenin a chemico biological insight in NIDDM. Chem Biol Interact 2013;206:403-10.
24. Uemura T, Hirai S, Mizoguchi N, Goto T, Lee J-Y, Taketani K, Nakano Y, Shono J, Hoshino S, Tsuge N, et al. Diosgenin present in fenugreek improves glucose metabolism by promoting adipocyte differentiation and inhibiting inflammation in adipose tissues. Mol Nutr Food Res 2010;54:1596-608.
25. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH, Hotamisligil GS. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457-61.
26. Wang H, Kouri G, Wollheim CB. ER stress and SREBP-1 activation are implicated in beta-cell glucolipotoxicity. J Cell Sci 2005;118:3905-15.
27. Lim S, Meigs JB. Ectopic fat and cardiometabolic and vascular risk. Int J Cardiol 2013;169:166-76.
28. Morelli M, Gaggini M, Daniele G, Marraccini P, Sicari R, Gastaldelli A. Ectopic fat: the true culprit linking obesity and cardiovascular disease? Thromb Haemost 2013;110:651-60.
29. Shimabukuro M, Kozuka C, Taira S, Yabiku K, Dagvasumberel M, Ishida M, Matsumoto S, Yagi S, Fukuda D, Yamakawa K, et al. Ectopic fat deposition and global cardiometabolic risk: new paradigm in cardiovascular medicine. J Med Invest 2013;60:1-14.
30. Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 2014;34:1155-61.
31. Lim S, Meigs JB. Links between ectopic fat and vascular disease in humans. Arterioscler Thromb Vasc Biol 2014;34:1820-6.
32. Huang YY, Gusdon AM, Qu S. Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies. Lipids Health Dis 2013;12:171.
33. Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis 2014;18:19-31.
34. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-31.
35. Edwards PA, Kast HR, Anisfeld AM. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res 2002;43:2-12.
36. Uemura T, Goto T, Kang MS, Mizoguchi N, Hirai S, Lee JY, Nakano Y, Shono J, Hoshino S, Taketani K, et al. Diosgenin, the main aglycon of fenugreek, inhibits LXR alpha activity in HepG2 cells and decreases plasma and hepatic triglycerides in obese diabetic mice. J Nutr 2011;141:17-23.
37. Turer AT, Hill JA, Elmquist JK, Scherer PE. Adipose tissue biology and cardiomyopathy: translational implications. Circ Res 2012;111:1565-77.
38. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell 2014;156:20-44.
39. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012;55:2319-26.
40. Bluher M. Adipokines-removing road blocks to obesity and diabetes therapy. Mol Metab 2014;3:230-40.
41. Mraz M, Haluzik M. The role of adipose tissue immune cells in obesity and low-grade inflammation. J Endocrinol 2014;222:R113-27.
42. Spiegelman BM. Peroxisome proliferator-activated receptor gamma: a key regulator of adipogenesis and systemic insulin sensitivity. Eur J Med Res 1997;2:457-64.
43. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab 2012;23:205-15.
44. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. PPAR gamma signaling and metabolism: the good, the bad and the future. Nat Med 2013;19:557-66.
45. Temel RE, Brown JM, Ma Y, Tang W, Rudel LL, Ioannou YA, Davies JP, Yu L. Diosgenin stimulation of fecal cholesterol excretion in mice is not NPC1L1 dependent. J Lipid Res 2009;50:915-23.
46. Tang W, Jia L, Ma Y, Xie P, Haywood J, Dawson PA, Li J, Yu L. Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-Like 1 only in liver. Biochim Biophys Acta 2011;1811:549-55.
47. Feng D, Ohlsson L, Duan RD. Curcumin inhibits cholesterol uptake in Caco-2 cells by down-regulation of NPC1L1 expression. Lipids Health Dis 2010;9:40.
48. Liu K, Zhao W, Gao X, Huang F, Kou J, Liu B. Diosgenin ameliorates palmitate-induced endothelial dysfunction and insulin resistance via blocking IKKbeta and IRS-1 pathways. Atherosclerosis 2012;223:350-8.
49. Manivannan J, Balamurugan E, Silambarasan T, Raja B. Diosgenin improves vascular function by increasing aortic eNOS expression, normalize dyslipidemia and ACE activity in chronic renal failure rats. Mol Cell Biochem 2013;384:113-20.
50. Manivannan J, Shanthakumar J, Arunagiri P, Raja B, Balamurugan E. Diosgenin interferes coronary vasoconstriction and inhibits osteochondrogenic transdifferentiation of aortic VSMC in CRF rats. Biochimie 2014;102:183-7.
51. Salimeh A, Mohammadi M, Rashidi B. Preconditioning with diosgenin and treadmill exercise preserves the cardiac toxicity of isoproterenol in rats. J Physiol Biochem 2013;69:255-65.
52. Ahmed LA, Obaid AA, Zaki HF, Agha AM. Role of oxidative stress, inflammation, nitric oxide and transforming growth factor-beta in the protective effect of diosgenin in monocrotaline-induced pulmonary hypertension in rats. Eur J Pharmacol 2014;740:379-87.
53. Badalzadeh R, Yousefi B, Majidinia M, Ebrahimi H. Anti-arrhythmic effect of diosgenin in reperfusion-induced myocardial injury in a rat model: activation of nitric oxide system and mitochondrial KATP channel. J Physiol Sci 2014;64:393-400.
54. Ebrahimi H, Badalzadeh R, Mohammadi M, Yousefi B. Diosgenin attenuates inflammatory response induced by myocardial reperfusion injury: role of mitochondrial ATP-sensitive potassium channels. J Physiol Biochem 2014;70:425-32.
55. Manivannan J, Barathkumar TR, Sivasubramanian J, Arunagiri P, Raja B, Balamurugan E. Diosgenin attenuates vascular calcification in chronic renal failure rats. Mol Cell Biochem 2013;378:9-18.
56. Fowden L, Pratt HM, Smith A. 4-Hydroxyisoleucine from seed of Trigonella-Foenum-Graecum. Phytochemistry 1973;12:1707-11.
57. Sauvaire Y, Petit P, Broca C, Manteghetti M, Baissac Y, Fernandez-Alvarez J, Gross R, RoyeM, Leconte A, Gomis R, et al. 4-Hydroxyisoleucine: a novel amino acid potentiator of insulin secretion. Diabetes 1998;47:206-10.
58. Sauvaire Y, Girardon P, Baccou JC, Risterucci AM. Changes in growth, proteins and free amino acids of developing seed and pod of fenugreek. Phytochemistry 1984;23:479-86.
59. Broca C, Gross R, Petit P, Sauvaire Y, ManteghettiM, TournierM,Masiello P, Gomis R, Ribes G. 4-Hydroxyisoleucine: experimental evidence of its insulinotropic and antidiabetic properties. Am J Physiol 1999;277:E617-23.
60. Broca C, Manteghetti M, Gross R, Baissac Y, Jacob M, Petit P, Sauvaire Y, Ribes G. 4-Hydroxyisoleucine: effects of synthetic and natural analogues on insulin secretion. Eur J Pharmacol 2000;390:339-45.
61. Broca C, Breil V, Cruciani-Guglielmacci C, Manteghetti M, Rouault C, Derouet M, Rizkalla S, Pau B, Petit P, Ribes G, et al. Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat. Am J Physiol Endocrinol Metab 2004;287:E463-71.
62. Narender T, Puri A. Shweta, Khaliq T, Saxena R, Bhatia G, Chandra R. 4-Hydroxyisoleucine an unusual amino acid as antidyslipidemic and antihyperglycemic agent. Bioorg Med Chem Lett 2006;16:293-6.
63. Haeri MR, Izaddoost M, Ardekani MRS, Nobar MR, White KN. The effect of fenugreek 4-hydroxyisoleucine on liver function biomarkers and glucose in diabetic and fructose-fed rats. Phytother Res 2009;23:61-4.
64. Singh AB, Tamarkar AK, Narender T, Srivastava AK. Antihyperglycaemic effect of an unusual amino acid (4-hydroxyisoleucine) in C57BL/KsJ-db/db mice. Nat Prod Res 2010;24:258-65.
65. Haeri MR, Limaki HK, White CJ, White KN. Non-insulin dependent anti-diabetic activity of (2S, 3R, 4S) 4-hydroxyisoleucine of fenugreek (Trigonella foenum graecum) in streptozotocin-induced type I diabetic rats. Phytomedicine 2012;19:571-4.
66. Jaiswal N, Maurya CK, Venkateswarlu K, Sukanya P, Srivastava AK, Narender T, Tamrakar AK. 4-Hydroxyisoleucine stimulates glucose uptake by increasing surface GLUT4 level in skeletal muscle cells via phosphatidylinositol-3-kinase-dependent pathway. Eur J Nutr 2012;51:893-8.
67. Maurya CK, Singh R, Jaiswal N, Venkateswarlu K, Narender T, Tamrakar AK. 4-Hydroxyisoleucine ameliorates fatty acid-induced insulin resistance and inflammatory response in skeletal muscle cells. Mol Cell Endocrinol 2014;395:51-60.
68. Yu H, Wu M, Lu FR, Xie J, Zheng N, Qin Y, Gao F, Du W, Jian LM. Effect of trigonella foenum-graecum 4-hydroxyisoleucine on high-glucose induced insulin resistance in 3T3-L1 adipocytes of mice. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi [Chinese journal of integrated traditional andWestern medicine] Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban 2013;33:1394-9.
69. Jennings AM,Wilson RM,Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 1989;12:203-8.
70. Overby NC, Sonestedt E, Laaksonen DE, Birgisdottir BE. Dietary fiber and the glycemic index: a background paper for the Nordic Nutrition Recommendations 2012. Food Nutr Res 2013;57.
71. Silva FM, Kramer CK, de Almeida JC, Steemburgo T, Gross JL, Azevedo MJ. Fiber intake and glycemic control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials. Nutr Rev 2013;71:790-801.
72. Roberts KT. The potential of fenugreek (Trigonella foenum-graecum) as a functional food and nutraceutical and its effects on glycemia and lipidemia. J Med Food 2011;14:1485-9.
73. Kumar P, Bhandari U, Jamadagni S. Fenugreek seed extract inhibit fat accumulation and ameliorates dyslipidemia in high fat diet-induced obese rats. Biomed Res Int 2014;2014:606021.
74. Doyle JP, Lyons G, Morris ER. New proposals on "hyperentanglement" of galactomannans: solution viscosity of fenugreek gum under neutral and alkaline conditions. Food Hydrocoll 2009;23:1501-10.
75. Hannan JMA, Ali L, Rokeya B, Khaleque J, Akhter M, Flatt PR, Abdel-Wahab YHA. Soluble dietary fibre fraction of Trigonella foenumgraecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action. Br J Nutr 2007;97:514-21.
76. Srichamroen A, Thomson AB, Field CJ, Basu TK. In vitro intestinal glucose uptake is inhibited by galactomannan from Canadian fenugreek seed (Trigonella foenum graecum L) in genetically lean and obese rats. Nutr Res 2009;29:49-54.
77. Hamden K, Jaouadi B, Carreau S, Bejar S, Elfeki A. Inhibitory effect of fenugreek galactomannan on digestive enzymes related to diabetes, hyperlipidemia, and liver-kidney dysfunctions. Biotechnol Bioprocess Eng 2010;15:407-13.
78. Ramulu P, Giridharan NV, Udayasekhararao P. Hypolipidemic effect of soluble dietary fiber (galactomannan) isolated from fenugreek seeds in WNIN (GR-Ob) obese rats. J Med Plants Res 2011;5:4804-13.
79. Eastwood M, Kritchevsky D. Dietary fiber: how did we get where we are? Annu Rev Nutr 2005;25:1-8.
80. Oh S-H, Park H-D, Ki C-S, Choe Y-H, Lee S-Y. Biochemical and molecular investigation of two Korean patients with glycogen storage disease type III. Clin Chem Lab Med 2008;46:1245-9.
81. Ku S, You HJ, Ji GE. Enhancement of anti-tumorigenic polysaccharide production, adhesion, and branch formation of bifidobacterium bifidum BGN4 by phytic acid. Food Sci Biotechnol 2009;18:749-54.
82. Heo SJ, Hwang JY, Choi JI, Han JS, Kim HJ, Jeon YJ. Diphlorethohy-droxycarmalol isolated from Ishige okamurae, a brown algae, a potent alpha-glucosidase and alpha-amylase inhibitor, alleviates postprandial hyperglycemia in diabetic mice. Eur J Pharmacol 2009;615:252-6.
83. Hannan JM, Rokeya B, Faruque O, Nahar N, Mosihuzzaman M, Azad Khan AK, Ali L. Effect of soluble dietary fibre fraction of Trigonella foenum graecum on glycemic, insulinemic, lipidemic and platelet aggregation status of Type 2 diabetic model rats. J Ethnopharmacol 2003;88:73-7.
84. Boban PT, Nambisan B, Sudhakaran PR. Hypolipidaemic effect of chemically different mucilages in rats: a comparative study. Br J Nutr 2006;96:1021-9.
85. Venkatesan N, Devaraj SN, Devaraj H. A fibre cocktail of fenugreek, guar gum and wheat bran reduces oxidative modification of LDL induced by an atherogenic diet in rats. Mol Cell Biochem 2007;294:145-53.
86. Srichamroen A, Field CJ, Thomson AB, Basu TK. The modifying effects of galactomannan from Canadian-grown fenugreek (Trigonella foenumgraecum L.) on the glycemic and lipidemic status in rats. J Clin Biochem Nutr 2008;43:167-74.
87. Neelakantan N, Narayanan M, de Souza RJ, van Dam RM. Effect of fenugreek (Trigonella foenum-graecum L.) intake on glycemia: a meta-analysis of clinical trials. Nutr J 2014;13:7.
88. Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol 2014;pii:S2213-8587(14)70134-2.
89. Moreno-Indias I, Cardona F, Tinahones FJ, Queipo-Ortuño MI. Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. Front Microbiol 2014;5:190.
90. Shoaie S, Nielsen J. Elucidating the interactions between the human gut microbiota and its host through metabolic modeling. Front Genet 2014;5:86.
91. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013;341:1241214.
92. Walsh CJ, Guinane CM, O'Toole PW, Cotter PD. Beneficial modulation of the gut microbiota. FEBS Lett 2014;588:4120-30.
93. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505:559-63.